U.S. biotechnology company Biogen has completed the acquisition of UK clinical-stage gene therapy company Nightstar Therapeutics in an $800 million deal.
Biogen said that Nightstar will accelerate its entry into ophthalmology by contributing two mid-to late-stage gene therapy assets.
Annually, Nightstar Therapeutics generates approximately $2.1 million in revenue.
Recently, Biogen was planning to purchase U.S. pharmaceutical company Pfizer Inc.’s experimental treatment for a symptom associated with schizophrenia in a nearly $600 million transaction.